latest news releases from the newsroom
StockGuru.com Announces Profile Coverage of Neuroscience Therapy Corporation
DALLAS, April 5, 2006 (PRIMEZONE) -- John Pentony, Publisher of StockGuru.com, announced today that the web site is initiating Profile Coverage for Neuroscience Therapy Corporation (Pink Sheets:NPYC). The P-Stim Electro Stimulation device and the Multi-Point stylus. It is capable of relieving pain almost anywhere in the body and has the potential to treat many other clinical conditions. This device has been used on several thousand patients in Europe.
Horizon Offshore Inc.
Horizon Offshore Provides First Quarter and Fiscal Year 2006 Financial Guidance
HOUSTON, April 5, 2006 (PRIMEZONE) -- Horizon Offshore, Inc. (OTCBB:HOFF) announced financial guidance today for the first quarter of 2006 and fiscal year 2006. The Company announced that it expects to generate earnings before interest, taxes, depreciation and amortization (EBITDA), as defined below, of between $37 million and $39 million for the first quarter of 2006 and between $135 million and $150 million for the full fiscal year of 2006. This compares to EBITDA of $0.6 million for the first quarter of 2005 and $50.7 million for all of 2005.
XsunX Development Team Adds Nano-Crystalline Specialists
ALISO VIEJO, Calif., April 5, 2006 (PRIMEZONE) -- XsunX, Inc. (OTCBB:XSNX), developer of Power Glass(r) -- an innovative solar technology that is intended to allow glass windows to produce electricity from the power of the sun, today announced the expansion of its development team to include additional senior scientists specializing in nano-crystalline thin-film technology. The expansion of the development team comes as the Company prepares to complete the addition of nano-crystalline development chambers to existing R&D systems as part of the development of a new hybrid solar-cell design employing a patent pending 4-terminal approach. The design combines aspects of the Company's Power Glass thin-film technology with that of nano-crystalline solar-cell design, which the Company believes holds the promise of lower cost, higher-efficiency, flexible and lighter-weight solar cells.
Discovery Laboratories, Inc.
Discovery Labs Receives Second Approvable Letter From FDA for Surfaxin for RDS
WARRINGTON, Pa., April 5, 2006 (PRIMEZONE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that it has received a second Approvable Letter from the U.S. Food and Drug Administration (FDA) for Discovery's lead product candidate, Surfaxin(r) (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. Surfaxin is a precision-engineered, peptide-containing, synthetic surfactant that is designed to closely mimic the function of natural human lung surfactant and represents a potential alternative to animal-derived surfactants. Discovery will hold a conference call today at 8:45 AM EDT. The call in number is 866-332-5218.
BOWE SYSTEC AG
BOWE SYSTEC Achieves own Prognosis in Financial Year 2005
AUGSBURG, Germany, April 5, 2006 (PRIMEZONE) -- With sales above EUR 460 million and results of more than EUR 17.5 million BOWE SYSTEC Group was able to meet its own prognosis. As the Management Board reported at today's press briefing on annual results, the company achieved consolidated sales of EUR 461.9 million. The net result reached EUR 19.0 million. The consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS).
Helvetia Patria Holding
2005 Financial Results: Helvetia Patria on Course for Success
ST. GALLEN, Switzerland, April 5, 2006 (PRIMEZONE) -- The Helvetia Patria Group, which is active throughout Europe, has reported after-tax profit of CHF 301.9 million for 2005 (2004: CHF 222.6 million). In addition to investment business, non-life business delivered the largest contribution to this improved result, accounting for CHF 262.5 million (+ 80.2 per cent) of Group profit before tax. Consolidated shareholders' equity rose by 21.6 per cent to CHF 2,480.8 million (2004: CHF 2,040.7 million). Based on this excellent result, a dividend increase of 63.6 per cent or CHF 3.50 to CHF 9.00 per share will be proposed to the Annual General Meeting of Shareholders.
St. Joseph, Inc.
St. Joseph, Inc. Reports That it Has Signed a Letter of Intent to Acquire Intellamed, Inc.
TULSA, Okla., April 4, 2006 (PRIMEZONE) -- St. Joseph, Inc. (OTCBB:STJO) announced today that President, John H. Simmons has signed a non-binding letter of intent to acquire Intellamed, Inc., a private company, as a wholly owned subsidiary. Intellamed is a Texas based medical asset management company whose medical services and equipment divisions facilitate the procurement and support of medical equipment to over 3,600 healthcare facilities throughout the United States. The acquisition is subject to customary due diligence, approval by the Board of Directors, and the execution of a definitive agreement.
Glancy Binkow & Goldberg LLP
Glancy Binkow & Goldberg LLP, Announces Court Decision That Shareholders are Allowed to Pursue Claims in Class Action Lawsuit Filed Against Staktek Holdings, Inc. -- STAK
LOS ANGELES, April 4, 2006 (PRIMEZONE) -- Los Angeles, CA - Glancy Binkow & Goldberg LLP is pleased to announce that it has successfully defeated defendants' motions to dismiss plaintiffs' Amended Complaint, thereby permitting shareholder plaintiffs to pursue securities claims against Staktek Holdings, Inc. ("Staktek")(Nasdaq:STAK) and Staktek officers and directors Joseph C. Aragona, James W. Cady and William Kirk Patterson. Glancy Binkow & Goldberg LLP was previously appointed Lead Counsel in the Class Action lawsuit filed in the United States District Court for the Western District of Texas on behalf of shareholders. The action focuses on the defendants' failure to disclose an ongoing D RAM shortage and a production shift in the semiconductor industry to planar technologies. Glancy Binkow & Goldberg LLP has significant experience in prosecuting class actions, and substantial expertise in actions involving corporate fraud.